Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to ...

Patients with JIA-associated uveitis who discontinued adalimumab had higher recurrence rates than those who continued the ...

After combing through 4,000 existing medications, an artificial intelligence tool helped uncover one that saved the life of a ...

Researchers used an AI-driven approach to identify adalimumab as a potential life-saving treatment for idiopathic ...

Juvenile idiopathic arthritis is the most common chronic systemic disease associated with uveitis in childhood. Uveitis occurs in 11–22% of children with juvenile idiopathic arthritis.1 Due to the ...

#Data provided for the iv. administration only. ADM: Adalimumab; AUC 0-∞: Area under the plasma concentration-time curve from time zero to infinity; CL/F: Apparent total clearance of the drug ...

Hidradenitis suppurativa is managed with biologics like adalimumab and secukinumab, approved for moderate-to-severe cases. Adalimumab, a TNF-α inhibitor, was FDA-approved in 2015, while ...

SB5, an adalimumab biosimilar approved in the US, is showing to be safe and effective for patients with psoriasis in the long ...

This case study explores a rare overlap of hidradenitis suppurativa and porokeratosis, as well as highlights the unique ...

Opens in a new tab or window Serum level of inflammatory marker C-reactive protein (CRP) predicted response to adalimumab (Humira) treatment for patients with hidradenitis suppurativa, post hoc ...

Number 2: Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of ...